

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[About Us](#)

[Tangible Materials Available for Licensing](#)

[Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA

In addition, they lack expression of both p53 (homozygous deletion) and FHIT (Fragile Histidine Triad) tumor-suppressor proteins. The Calu-1 cells are intrinsically resistant to erlotinib, an EGFR tyrosine kinase inhibitor used in the treatment of NSCLC patients. These cells are capable of forming tumors in immunocompromised mice.

Source

This cell line was established in 1971 from a metastatic site (pleura) in a 47-year-old Caucasian male with epidermoid carcinoma of the lung.

Inventors

- Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

- Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. *Journal of the National Cancer Institute* 59: 221-226 (PubMed ID: [327080](#))
- Cavazzoni A et al. (2007) Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line. *Cancer Letters* 246: 69-81 (PubMed ID: [16616810](#))

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

- Express License: For internal research purposes by a for-profit entity: Fill out MSK's Core Express License; see [here](#) for links to the online fillable Core Express License, as well as a PDF version. For detailed guidance on how to fill out this webform, see [here](#) . Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to \$10,000 must be made by credit card.
- Commercial License: Contact MSK's Tangible Research Materials team at TRMOTDRTM@mskcc.org .
- For non-licensing requests from academic-research institutions : Contact MSK's Antibody & Bioresource Core Facility at skiabcf@mskcc.org .

Stage of Development

Ready to use

Indications

[Cancer](#) › [Lung](#)

Types

[Research Tools](#) › [Cell Lines](#)

© 2026 Memorial Sloan Kettering Cancer Center